Hypertrophic cardiomyopathy: Management issues in the new millennium

Current Cardiology Reports

Volumn 4, Issue 3, 2002, Pages 226-232

  Thaman, Rajesh ^a   Firoozi, Sami ^a   Hamid, M S ^a   Mckenna, William J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ONSET AGE; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH;

AGE OF ONSET; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 0036580926     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0055-z     Document Type: Article

References (44)

1. Maron BJ, Gardin JM, Flack JM, et al.: Prevalence of hypertrophic cardiomyopathy in a general population of young adults; echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995, 92:785-789.
2. McKenna WJ, Deanfield J, Faruqui A, et al.: Prognosis in hypertrophic cardiomyopathy. Role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981, 47:532-538.
3. Maron BJ, Wolfson JK, Epstein SE, Roberts WC: Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986, 8:545.
4. Kimura A, Harada H, Park J-E, et al.: Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997, 16:379-382.
5. Jarcho JA, McKenna WJ, Pare JA, et al.: Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989, 321:1372-1378.
6. Thierfelder L, MacRae C, Watkins H, et al.: A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A 1993, 90:6270-6274.
7. Watkins H, McRae C, Thierfelder L, et al.: A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993, 3:333-337.
8. Bonne G, Carrier L, Bercovici J, et al.: Cardiac myosin binding protein C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:438-440.
9. Watkins H, Rozenzweig A, Hwang DS, et al.: Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992, 326:1108-1114.
10. Poetter K, Jiang H, Hassanzadeh S, et al.: Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996, 13:63-69.
11. Oslon TM, Doan TP, Kishimoto NY, et al.: Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000, 32:1687-1694.
12. Blaire E, Redwood C, Ashrafian H, et al.: Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial HCM: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001, 10:1215-1220.
13. Lechin M, Quinones MA, Omran A, et al.: Angiotensin converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995, 92:1808-1812.
14. Niimura H, Bachinski LL, Sangwatanaroj S, et al.: Mutations in the gene for cardiac-binding protein C and late onset familial hypertrophic cardiomyopathy. N Eng J Med 1998, 338:1248-1257.
15. Elliott PM, D'Cruz L, McKenna WJ: Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiac troponin T gene. N Engl J Med 1999, 341:1855-1856.
16. Sharma S, Elliott PM, Whyte G, et al.: Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000, 36:864-870.
17. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775-785. Nice review of the management of HCM.
18. Bonow RO, Dilsizian V, Rosing DR, et al.: Verapamil induced improvement in left diastolic ventricular filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy. Short and long term effects. Circulation 1985, 72:853-864.
19. Elliott PM, Kaski JC, Prasad K, et al.: Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 1996, 17:1056-1064.
20. Nicod P, Polikar R, Peterson KL: Hypertrophic cardiomyopathy and sudden death. N Eng J Med 1988, 318:1255-1257.
21. Cannon RO, Dilsizian V, O'Gara P, et al.: Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991, 83:1660.
22. Camici P, Chiriatti G, Lorenzoni R, et al.: Coronary vasodilatation is impaired in both hypertrophied and non hypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with Nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991, 17:879-886.
23. Maron BJ, Merrill WH, Freier PA, et al.: Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978, 57:1205-1213.
24. Williams WG, Wigle ED, Rakowski H, et al.: Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987, 76(Suppl V):V104-V108.
25. Robbins RC, Stinson EB: Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thoac Cardiovas Surg 1996, 111:586-594.
26. McCully RB, Nishimura RA, Tajik J, et al.: Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996, 94:467-471.
27. Spirito P, Maron B: Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999, 33:1071-1075. A nice review examining the therapeutic options available for the treatment of obstructive HCM.
28. Fananapazir L, Epstein ND, Curiel RV, et al.: Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994, 90:2731-2742.
29. Nishimura RA, Trusty JM, Hayes DL, et al.: Dual chamber pacing for hypertrophic cardiomyopathy: a randomised double-blind crossover trial. J Am Coll Cardiol 1997, 29:435-441.
30. Kappenberger L, Linde C, Daubert C, et al., (PIC study Group): Pacing in hypertrophic obstructive cardiomyopathy. A randomised crossover study. Euro Heart J 1997, 18:1249-1256.
31. Figwort U: Non-surgical myocardial reduction for hypertrophy obstructive cardiomyopathy. Lancet 1995, 346:211-214.
32. Knight C, Kurbaan AS, Seggewiss H, et al.: Non-surgical reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997, 95:2075-2081.
33. Sadoul N, Prasad K, Slade AKB, et al.: Abnormal blood pressure response during exercise is an independent marker of sudden death in young patients with hypertrophic cardiomyopathy. Circulation 1997, in press.
34. Frenneaux MP, Counihan PJ, Caforio A, et al.: Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990, 82:1995-2002.
35. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ: Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84:686-696.
36. Spirito P, Bellone P, Harris KM, et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785. This article demonstrates that extreme left ventricular hypertrophy is associated with an increased risk of sudden death.
37. Elliott PM, Gimeno Blanes JR, et al.: Relation between severity of LVH and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:407-408. This article demonstrates that although a wall thickness of 30 mm or more in combination with other risk factors does increase the likelihood of sudden death, the presence of mild hypertrophy cannot be used to reassure individuals.
38. Elliott PM, Poloniecki J, Dickie S, et al.: Sudden death in hypertrophic cardiomyopathy: identification of high-risk patients. J Am Coll Cardiol 2000, 36:2212-2218. This article demonstrates that patients at increased risk of sudden death can readily be detected using noninvasive techniques. Management strategies can then be determined based on the presence of risk markers.
39. McKenna WJ, Oakley CM, Krikler DM, et al.: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985, 53:412-416.
40. Elliott PM, Sharma S, Poloniecki J, et al.: Amiodarone and sudden death in hypertrophic cardiomyopathy [abstract]. Circulation 1997, in press.
41. Maron BJ, Shen WK, Link MS, et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365-373. The effectiveness of the implantable defibrillator in terminating ventricular arrhythmias in hypertrophic cardiomyopathy is demonstrated in this article.
42. Primo J, Geelen P, Brugada J, et al.: Hypertrophic cardiomyopathy: role of the implantable cardioverter defibrillator. J Am Coll Cardiol 1998, 31:1081-1085.
43. Silka MJ, Kron J, Dunnigan A, Dick M: Sudden cardiac death and the use of implantable cardioverter-defibrillator in paediatric patients. Circulation 1993, 87:800-807.
44. Kron J, Oliver RP, Norsted S, Silka MJ: The automatic implantable cardioverter defibrillator in young patients. J Am Coll Cardiol 1990, 16:896-902.